/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

H

Hiroki Hara

TDK (Japan)(JP)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

473

Papers

15.3K

Citations

45

h-index

133

i10-index

Hiroki Hara is an academic researcher from TDK (Japan). The author has contributed to research in topics: Gastric Cancer Management and Outcomes & Colorectal Cancer Treatments and Studies & Cancer Immunotherapy and Biomarkers. The author has an h-index of 45, co-authored 403 publications.

ORCID: 0000-0003-3881-9815

Research Topics

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers Esophageal Cancer Research and Treatment Gastrointestinal Tumor Research and Treatment

Papers by this author

works

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

2021 · The Lancet · 1,479 citations

https://doi.org/10.1016/s0140-6736(21)01234-4

Jong‐Mu Sun Lin Shen Manish A. Shah Peter C. Enzinger

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 · The Lancet Oncology · 379 citations

https://doi.org/10.1016/s1470-2045(17)30181-x

Toshihiro Kudo Yasuo Hamamoto Ken Kato Takashi Ura

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

2019 · Gastric Cancer · 242 citations

https://doi.org/10.1007/s10120-018-00909-5

Yung‐Jue Bang Yoon‐Koo Kang Daniel V.T. Catenacci Kei Muro

Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head‐and‐neck cancer

2022 · Cancer Medicine · 59 citations

https://doi.org/10.1002/cam4.4593

Yuichiro Doki Makoto Ueno Chih‐Hung Hsu Do‐Youn Oh

TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma

2020 · BMC Cancer · 52 citations

https://doi.org/10.1186/s12885-020-06716-5

Hideaki Bando Daisuke Kotani Takahiro Tsushima Hiroki Hara

Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)

2020 · Esophagus · 43 citations

https://doi.org/10.1007/s10388-020-00794-x

Masanobu Takahashi Ken Kato Morihito Okada Keisho Chìn

Research topics

topics

Gastric Cancer Management and Outcomes

Colorectal Cancer Treatments and Studies

Cancer Immunotherapy and Biomarkers

Esophageal Cancer Research and Treatment

Gastrointestinal Tumor Research and Treatment

Chat about Author

Papers

Chat

Click to start Chat